Last reviewed · How we verify

NCT06782997: ERGDIAB

Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diabetic Retinopathy.

Recruiting now Last updated 28 July 2025
What this trial tests

trial testing Electroretinogram in Diabetic Retinopathy in 270 participants. Currently enrolling.

Timeline
17 June 2025
Primary endpoint
17 December 2026
17 December 2026

Quick facts

Lead sponsorCHU de Reims
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment270
Start date17 June 2025
Primary completion17 December 2026
Estimated completion17 December 2026
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

CHU de Reims — full company profile →

Who can join

18 and older, any sex, with Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus and the leading cause of preventable blindness in working-age individuals. Early screening for DR is a public health issue. The gold standard is fundoscopy interpreted by an ophthalmologist. In France, in 2020, it was estimated that one-third of diabetic patients had not seen an ophthalmologist in over two years. Recently, a portable electroretinogram (ERG), which provides a physiological and non-invasive assessment of retinal cell function, has been developed. It combines pupillary responses through an infrared-sensitive camera, the implicit time and the response amplitude to brief white light stimuli. The result is expressed as an overall score (DR score), considered abnormal if it is \< 7 or \> 23.4. The sensitivity of the ERG for screening diabetic retinopathy is estimated at 80%, and its specificity at 82%, compared to conventional imaging. Additionally, it has been shown that poor glycemic control is associated with an increase in implicit time in preclinical DR. This test could therefore detect earlier changes than imaging results. To date, it is not considered the gold standard in France. The investigators aim to test this hypothesis. The investigators propose a prospective, bi-center study to evaluate the performance of the ERG, performed and interpreted by an Advanced Practice Nurse (APN), compared to the gold standard of retinal imaging (retinography) interpreted remotely by an ophthalmologist.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Electroretinogram

Trials testing the same drug.

Other recruiting trials for Diabetic Retinopathy

Currently open trials in the same condition.

Other CHU de Reims trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06782997.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing